These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
88 related articles for article (PubMed ID: 12796596)
1. Oncogenes in male breast cancer. Idelevich E; Mozes M; Ben-Baruch N; Huszar M; Kruglikova A; Katsnelson R; Shani A Am J Clin Oncol; 2003 Jun; 26(3):259-61. PubMed ID: 12796596 [TBL] [Abstract][Full Text] [Related]
2. Prognostic significance of p53, bcl-2, and Bax expression in early breast cancer. Linjawi A; Kontogiannea M; Halwani F; Edwardes M; Meterissian S J Am Coll Surg; 2004 Jan; 198(1):83-90. PubMed ID: 14698315 [TBL] [Abstract][Full Text] [Related]
3. C-erbB-2 expression is a better predictor for survival than galectin-3 or p53 in early-stage breast cancer. Logullo AF; Lopes AB; Nonogaki S; Soares FA; Netto MM; Nishimoto IN; Brentani MM Oncol Rep; 2007 Jul; 18(1):121-6. PubMed ID: 17549356 [TBL] [Abstract][Full Text] [Related]
4. Immunohistochemical expression of bcl-2 in UICC stage I and III colorectal carcinoma patients: correlation with c-erbB-2, p53, ki-67, CD44, laminin and collagen IV in evaluating prognostic significance. Zavrides H; Zizi-Sermpetzoglou A; Elemenoglou I; Papatheofanis I; Peros G; Athanasas G; Panousopoulos D Pol J Pathol; 2006; 57(3):149-59. PubMed ID: 17219742 [TBL] [Abstract][Full Text] [Related]
5. [Comparative study of P 53, Bcl-2, and C-erbB-2 expression in low-grade papillary bladder tumors]. Ramos Soler D; Navarro Fos S; Villamón Fort R; Gil Salom M; Llombart Bosch A Arch Esp Urol; 2003 Apr; 56(3):277-85. PubMed ID: 12768988 [TBL] [Abstract][Full Text] [Related]
6. [Prognostic value of expression of FASE, HER-2/neu, bcl-2 and p53 in stage I non-small cell lung cancer]. Wang Y; Zhang XR; Fu J; Tan W; Zhang W Zhonghua Zhong Liu Za Zhi; 2004 Jun; 26(6):369-72. PubMed ID: 15312350 [TBL] [Abstract][Full Text] [Related]
7. The significance of c-erbB-2 overexpression and p53 expression in patients with axillary lymph node--negative breast cancer: a tissue microarray study. Ko SS; Na YS; Yoon CS; Park JY; Kim HS; Hur MH; Lee HK; Chun YK; Kang SS; Park BW; Lee JH Int J Surg Pathol; 2007 Apr; 15(2):98-109. PubMed ID: 17478762 [TBL] [Abstract][Full Text] [Related]
8. Relationship between AgNORs, MIB-1 and oncogene expression in male breast carcinoma and papillary superficial bladder neoplasm. Pich A; Margaria E; Chiusa L; Bortolin P; Palestro G Oncol Rep; 2003; 10(5):1329-35. PubMed ID: 12883702 [TBL] [Abstract][Full Text] [Related]
9. Bcl2, p53 and clinical outcome in a series of 138 operable breast cancer patients. Castiglione F; Sarotto I; Fontana V; Destefanis M; Venturino A; Ferro S; Cardaropoli S; Orengo MA; Porcile G Anticancer Res; 1999; 19(5C):4555-63. PubMed ID: 10650810 [TBL] [Abstract][Full Text] [Related]
10. The prognostic significance of multiple morphologic features and biologic markers in ductal carcinoma in situ of the breast: a study of a large cohort of patients treated with surgery alone. Cornfield DB; Palazzo JP; Schwartz GF; Goonewardene SA; Kovatich AJ; Chervoneva I; Hyslop T; Schwarting R Cancer; 2004 Jun; 100(11):2317-27. PubMed ID: 15160334 [TBL] [Abstract][Full Text] [Related]
11. Immunohistochemical expression of bcl-2 in Dukes' stage B and C colorectal carcinoma patients: correlation with p53 and ki-67 in evaluating prognostic significance. Zavrides H; Zizi-Sermpetzoglou A; Elemenoglou I; Papatheofanis I; Peros G; Athanasas G; Panousopoulos D Pol J Pathol; 2005; 56(4):179-85. PubMed ID: 16477877 [TBL] [Abstract][Full Text] [Related]
12. Prognostic significance of bcl-2 expression in stage III breast cancer patients who had received doxorubicin and cyclophosphamide followed by paclitaxel as adjuvant chemotherapy. Lee KH; Im SA; Oh DY; Lee SH; Chie EK; Han W; Kim DW; Kim TY; Park IA; Noh DY; Heo DS; Ha SW; Bang YJ BMC Cancer; 2007 Apr; 7():63. PubMed ID: 17430582 [TBL] [Abstract][Full Text] [Related]
13. p53 and c-erbB-2 as markers of resistance to adjuvant chemotherapy in breast cancer. Têtu B; Brisson J; Plante V; Bernard P Mod Pathol; 1998 Sep; 11(9):823-30. PubMed ID: 9758361 [TBL] [Abstract][Full Text] [Related]
14. Coexistence of HER2 over-expression and p53 protein accumulation is a strong prognostic molecular marker in breast cancer. Yamashita H; Nishio M; Toyama T; Sugiura H; Zhang Z; Kobayashi S; Iwase H Breast Cancer Res; 2004; 6(1):R24-30. PubMed ID: 14680497 [TBL] [Abstract][Full Text] [Related]
15. Oncogenes and male breast carcinoma: c-erbB-2 and p53 coexpression predicts a poor survival. Pich A; Margaria E; Chiusa L J Clin Oncol; 2000 Aug; 18(16):2948-56. PubMed ID: 10944127 [TBL] [Abstract][Full Text] [Related]
16. Comparative study of two androgen-induced markers (apolipoprotein D and pepsinogen C) in female and male breast carcinoma. Serra C; Vizoso F; Lamelas ML; Rodríguez JC; González LO; Merino AM; Baltasar A; Pérez-Vázquez MT; Medrano J Int J Surg Investig; 2000; 2(3):183-92. PubMed ID: 12678518 [TBL] [Abstract][Full Text] [Related]
17. Evaluation of P-glycoprotein, HER-2/ErbB-2, p53, and Bcl-2 in primary tumor and metachronous lung metastases in patients with high-grade osteosarcoma. Ferrari S; Bertoni F; Zanella L; Setola E; Bacchini P; Alberghini M; Versari M; Bacci G Cancer; 2004 May; 100(9):1936-42. PubMed ID: 15112275 [TBL] [Abstract][Full Text] [Related]
18. Clinical contribution of bcl-2, p53 and Ki-67 proteins in pancreatic ductal adenocarcinoma. Mäkinen K; Hakala T; Lipponen P; Alhava E; Eskelinen M Anticancer Res; 1998; 18(1B):615-8. PubMed ID: 9568186 [TBL] [Abstract][Full Text] [Related]
19. Prognostic significance of p53 and c-erbB-2 immunohistochemical evaluation in colorectal adenocarcinoma. Lazaris AC; Theodoropoulos GE; Anastassopoulos P; Nakopoulou L; Panoussopoulos D; Papadimitriou K Histol Histopathol; 1995 Jul; 10(3):661-8. PubMed ID: 7579815 [TBL] [Abstract][Full Text] [Related]
20. Bcl-2 protein expression is associated with p27 and p53 protein expressions and MIB-1 counts in breast cancer. Tsutsui S; Yasuda K; Suzuki K; Takeuchi H; Nishizaki T; Higashi H; Era S BMC Cancer; 2006 Jul; 6():187. PubMed ID: 16839413 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]